Результаты поиска

Emerging Insights into Granulomatous and Amyloidogenic Cardiomyopathies.

Background: Granulomatous and amyloidogenic cardiomyopathies are infiltrative conditions that can be fatal if left untreated. Among these, cardiac amyloidosis and cardiac sarcoidosis are significant but often underdiagnosed causes of heart failure, each serving as cardiac manifestations of broader systemic diseases. Advancements in imaging techniques and the emergence of novel therapies-particularly for cardiac amyloidosis-have brought these conditions into sharper focus for both clinicians and researchers. Methods: We conducted a comprehensive review of the literature by searching databases i

Совпадение в полном тексте источника
… While the treatment of AL is primarily managed by hematologists, it usually involves close collaboration with cardiologists to manage ongoing cardiac manifestations of the disease including congestive heart failure and arrhythmias. …

Сердечные биомаркеры для стратификации риска в недавно диагностированном миеломе высокого риска в пробе GMG-CONCEPT.

Сердечно-сосудистые неблагоприятные явления (CVAE) являются клиническими побочными эффектами во время лечения протеаозным ингибитором карфилзомиба. Мы изучили прогнозируемую ценность сердечных биомаркеров для начала CVAE у пациентов с недавно поставленным диагнозом множественной миэломы повышенного риска, обработанных изатуксимабом, карфиломибом, линалидомидом и дексаметазоном в исследовании GMG-CONCEPT (GMG-CONCEPT).NCT03104842). Пациенты, включенные в это перспективное, многоцентровое корреляционное исследование, имеют право на получение пробы сыворотки до начала лечения и на ≥ 1 позднее был

Euthanasia as a safeguard for living: Anticipation and incurable cancer in a Colombian context.

This article builds on years of ethnographic conversations I sustained with my father, 89, who lives in Colombia. Soon after getting diagnosed with an incurable Multiple Myeloma-a cancer known for unleashing prolonged and painful agonies-he withdrew from oncology treatments and secured access to euthanasia (assisted-dying) on his own, bypassing medico-insurance guidelines created to regulate this medical practice and prevent abuses. Eight years after withdrawing treatments, my dad is still alive. His case shines a light on how securing access to euthanasia may have had unintended therapeutic e

Mitigating Doxorubicin-Induced Cardiotoxicity through Quercetin Intervention: An Experimental Study in Rats.

Doxorubicin (DOX) is an effective anticancer drug, but its use is limited by dose-dependent heart toxicity. Quercetin is a natural antioxidant frequently studied for its beneficial properties. Moreover, a wide range of dietary supplements are available for human use. This in vivo study aimed to explore the potential cardioprotective effects of quercetin in chronic DOX treatment. A total of 32 Wistar rats were randomly divided into four groups: control, DOX, DOX/Q-50, and DOX/Q-100, treated with saline, 2.5 mg/kg body-weight DOX, 2.5 mg/kg body-weight DOX + 50 mg quercetin, and 2.5 mg/kg body-w

Совпадение в полном тексте источника
… The study’s strengths lie in the consistent and homogeneous treatment of animals, overseen by experienced cardiologists, ensuring uniformity in experimental conditions and robust data analysis. …

The Risk of Sarcoidosis Misdiagnosis and the Harmful Effect of Corticosteroids When the Disease Picture Is Incomplete.

Sarcoidosis is a complex granulomatous disease of unknown etiology. Due to the heterogeneity of the disease, the diagnosis remains challenging in many cases, often at the physician's discretion, requiring a thorough and complex investigation. Many other granulomatous diseases have the potential to mimic sarcoidosis, whether infectious, occupational, or autoimmune diseases and starting an unnecessary corticosteroid treatment can worsen the patient's prognosis, leading to side effects that can be harder to treat than the actual disease.

Review of cancer therapies for the perioperative physician.

Advances in cancer treatments over the past decades combining chemotherapy with novel technologies in immunotherapies, radiation therapies, and interventional radiology have prolonged life expectancy. Patients have more options for treatments of their primary or metastatic diseases. Increased procedural techniques amid an aging population with multiple comorbidities present risks and challenges in the perioperative period.Chemotherapy remains the mainstay of cancer treatment, can be given intraoperatively, and is combined with other treatment modalities. Immunotherapy is particular to cancer c

2022 NATIONAL CONGRESS OF THE ITALIAN SOCIETY OF HYPERTENSION (SIIA)

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Patients were monitored daily by CardioMEMS; if the cardiologist detected a tendency for pulmonary artery diastolic pressure (PAPd) to rise, patients were contacted for home therapeutic changes. If no further changes were possible, the patient was hospitalized for the infusion of Levosimendan. … Salvatore Hospital, L'Aquila, Italy; 2 President, Regional Associations of Ambulatory Cardiologists Introduction: Hypertension and LDL hypercholesterolemia often coexist, and their effective treatment has favourable implications for cardiovascular health. …

Determining Risk Factors Associated with Cardiovascular Complications in Patients with Acute Leukemia: A Systematic Review.

BackgroundPatients with acute leukemia (AL) are at heightened risk of cardiovascular complications due to both disease-related and treatment-related factors. These complications include heart failure, arrhythmias, myocardial infarction, and thromboembolic events which may significantly impact morbidity and mortality.ObjectiveTo identify the risk factors contributing to cardiovascular complications in patients with acute leukemia.MethodsThis systematic review was conducted according to the PRISMA reporting guideline. Multiple databases including PubMed, Scopus, IEEE Xplore, the Cochrane Library

Совпадение в полном тексте источника
… tamponade, Cardiac masses, Myocardial Hypertrophy, Leukemic infiltration of coronary arteries, Thrombotic occlusion, Pericardial Effusion, Arrhythmias and Conduction Abnormalities | Before Treatment to Late-Onset | Cardiac symptoms could be the first presentation of ALL, often leading to misdiagnosis by cardiologists …

American Society of Hematology 2026 guidelines on diagnosis of light chain amyloidosis.

BACKGROUND: Light chain (AL) amyloidosis is a rare disease caused by the misfolding of immunoglobulin light chains produced by a plasma cell dyscrasia. Patients can present with involvement of many organs, including the heart, kidneys, liver, nerves, and other sites, resulting in a high symptom burden. Timely and accurate diagnosis is important to prevent organ failure and improve patient survival. OBJECTIVE: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients and clinicians in the timely and effective diagnosis of AL amyloidosis. METH

Совпадение в полном тексте источника
… The target audience includes patients, community and academic hematologists, general practitioners, internists, nephrologists, cardiologists, neurologists, pathologists, and other clinicians, as well as decision-makers. … The panel included hematologists, cardiologists, an internist, a neurologist, a pathologist, and a nephrologist, who all had clinical and research expertise on the guideline topic, and 1 patient representative. …

Transferability of a US claims-based machine learning model for ATTRwt-CM identification: a retrospective evaluation in a German setting.

Cardiac amyloidosis (CA), a fatal and progressive cardiomyopathy is characterized by amyloid deposition within the myocardium. The main forms of CA include transthyretin amyloidosis (ATTR-CM; distinguished into a hereditary and wildtype form [ATTRv and ATTRwt]) and light-chain amyloidosis (AL). Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is increasingly recognized among heart failure (HF) patients, despite its underestimated prevalence as a rare disease. ATTR-CM is challenging to diagnose due to its broad phenotypic overlap with HF, yet a timely differentiation of CA is crucial, as

Совпадение в полном тексте источника
… All three subsets have been approved by cardiologists and neurologists. A RF ML model, developed by Huda et al 13 ., was employed for validation on the German data set. …

Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol.

BackgroundMetastatic pancreatic ductal adenocarcinoma (mPDAC) patients have very poor prognosis highlighting the urgent need of novel treatments. In this regard, repurposing non-oncology already-approved drugs might be an attractive strategy to offer more-effective treatment easily tested in clinical trials. Accumulating evidence suggests that epigenetic deregulation is a hallmark of cancer contributing to treatment resistance in several solid tumors, including PDAC. Histone deacetylase inhibitors (HDACi) are epigenetic drugs we have investigated preclinically and clinically as anticancer agen

Совпадение в полном тексте источника
… Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol. 2011;80(3):369–79. 44. Miyabayashi K, Nakagawa H, Koike K. …

Cardiovascular Considerations in Patients Undergoing Hematopoietic Cell Transplantation.

Opinion statementCardiac dysfunction is a serious adverse effect of cancer therapies that can interfere with quality of life and impact long-term survival in patients with cancer. Hematopoietic cell transplantation is a potentially curative therapy for many advanced hematologic malignancies and bone marrow failure syndromes, however is associated with several short- and long-term adverse effects, including importantly, cardiovascular toxicities. The goal of this review article is to describe the cardiovascular events that may develop before, during, and after hematopoietic cell transplantation

Совпадение в полном тексте источника
… Early detection of cardiac dysfunction via serum cardiac biomarkers, such as troponins and natriuretic peptides, is advised, with referrals to cardiologists for patients exhibiting cardiac dysfunction. Elevations in cardiac markers may precede findings on echocardiogram. …

Current Data and Future Perspectives on Patients with Atrial Fibrillation and Cancer

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Comments by a team of experts: Cardiologists and oncologists. Kardiol. Pol. 2023 doi: 10.33963/v.kp.96840. online ahead of print . 66. Isogai T., Saad A.M., Abushouk A.I., Shekhar S., Kuroda S., Gad M.M., Wazni O.M., Krishnaswamy A., Kapadia S.R. …

Exploring the Cardiotoxicity Spectrum of Anti-Cancer Treatments: Definition, Classification, and Diagnostic Pathways.

Early detection and treatment of cancer have led to a noticeable reduction in both mortality and morbidity. However, chemotherapy and radiotherapy could exert cardiovascular (CV) side effects, impacting survival and quality of life, independent of the oncologic prognosis. In this regard, a high clinical index of suspicion is required by the multidisciplinary care team in order to trigger specific laboratory tests (namely natriuretic peptides and high-sensitivity cardiac troponin) and appropriate imaging techniques (transthoracic echocardiography along with cardiac magnetic resonance, cardiac c

Совпадение в полном тексте источника
… In this regard, several scientific associations of cardiologists and oncologists have made an effort to better define the management of adverse sequelae of cancer therapy-related cardiovascular toxicity (CTR-CVT), leading to a new discipline known as cardio-oncology [ 4 , 5 , 6 ] ( Figure 1 and Figure …

Concurrent evolution of cancer cachexia and heart failure: bilateral effects exist.

Cancer cachexia is defined as a multifactorial syndrome of involuntary weight loss characterized by an ongoing loss of skeletal muscle mass and progressive functional impairment. It is postulated that cardiac dysfunction/atrophy parallels skeletal muscle atrophy in cancer cachexia. Cardiotoxic chemotherapy may additionally result in cardiac dysfunction and heart failure in some cancer patients. Heart failure thus may be a consequence of either ongoing cachexia or chemotherapy-induced cardiotoxicity; at the same time, heart failure can result in cachexia, especially muscle wasting. Therefore, t

Совпадение в полном тексте источника
… Collaboration between medical oncologists and cardiologists is essential to develop this area [ 43 ]. We must develop a clearer idea of which cancer patients could benefit from cardiac therapies. …

Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients.

The development of a wide range of novel antineoplastic therapies has improved the prognosis for patients with a wide range of malignancies, which has increased the number of cancer survivors substantially. Despite the oncological benefit, cancer survivors are exposed to short- and long-term adverse cardiovascular toxicities associated with anticancer therapies. Systemic hypertension, the most common comorbidity among cancer patients, is a major contributor to the increased risk for developing these adverse cardiovascular events. Cancer and hypertension have common risk factors, have overlappi

Совпадение в полном тексте источника
… A collaborative approach between cardiologists, (hemato)-oncologists, and cardiovascular specialists remains vital in the day-to-day management of patients with cancer and hypertension. … Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart. 2018;104:1995–2002. doi: 10.1136/heartjnl-2018-313726 107. Touyz RM, Herrmann SMS, Herrmann J. …

Extraglandular Manifestations of Sjögren’s Syndrome (SS): Dermatologic, Arthritic, Endocrine, Pulmonary, Cardiovascular, Gastroenterology, Renal, Urology, and Gynecologic Manifestations

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Indeed, the cardiologists have extended our familiar “normal” range of CRP to include lower levels of CRP (1–3 mg/L) as they measure “highly sensitive CRP (hsCRP)” as a measure of cardiovascular risk. … Indeed, an entirely new set of problems face the patient and rheumatologist, as the cardiologist pushes statins to higher levels in order to minimize the hsCRP with the instruction “better a little joint and muscle pain than a heart attack.” …

Clinical context and communication in shared decision-making about major surgery: Findings from a qualitative study with colorectal, orthopaedic and cardiac patients.

Increasing numbers of older people undergo major surgery in the United Kingdom (UK), with many at high risk of complications due to age, co-morbidities or frailty. This article reports on a study of such patients and their clinicians engaged in shared decision-making. Shared decision-making is a collaborative approach that seeks to value and centre patients' preferences, potentially addressing asymmetries of knowledge and power between clinicians and patients by countering medical authority with greater patient empowerment. We studied shared decision-making practices in the context of major su

Factors associated with medication adherence trajectory among patients treated with oral anticancer drugs: a multicentre cohort study.

PurposeOptimal medication adherence to oral systemic anticancer therapies (SACTs) is critical for effective cancer management. However, the factors influencing adherence, particularly in relation to the longitudinal course of the disease, remain poorly understood. This study aimed to identify factors associated with medication adherence trajectories among patients initiating oral SACTs.MethodsA multicentre cohort study was conducted among patients initiating oral SACTs and enrolled in a multidisciplinary risk management programme during day hospitalisation. Medication adherence trajectories we

Совпадение в полном тексте источника
… Other healthcare professional interventions, including those by psychologists, social workers, and cardiologists, could be consulted based on specific patient needs. …

Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management.

AL amyloidosis is characterized by a low-level expansion of an indolent, small plasma cell clone that produces amyloidogenic light chains. Amyloid aggregates or preceding intermediaries cause direct cell damage through their proteotoxicity, and amyloid deposits distort tissue architecture, and, eventually, lead to organ impairment. It is a rare, underdiagnosed disease with a diverse clinical presentation depending on the organ tropism of the amyloid fibrils; cardiac and renal involvement is most common, but any organ can be affected, excluding the central nervous system. A high level of awaren

Совпадение в полном тексте источника
… At all stages of treatment, major emphasis is given on supportive management which requires expert input from multiple specialties including cardiologists and nephrologists. Adverse event management and prevention and appropriate organ function support are key to treatment success (Table 3 ). …